RxDoctor Payments Data

Valeriy Sabodash, MD

Neurology · Sarasota, FLNPI 1003008533

Payments from drug & device makers

$40,079in general payments, 2019–2025

Across 529 payments — averaging $75.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$30K
  • AstraZeneca$1K
  • AbbVie$997
  • Sanofi$834
  • SK Life Science, Inc.$775
  • Novartis$739
  • plus $6K from 43 others

What the payments were for

  • Consulting fees$4,46811%
  • Speaking & faculty fees$20,98252%
  • Travel & lodging$2,8287%
  • Food & beverage$11,80229%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,079 in reported general payments places this provider in the 80th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$518,297
Medicare patients
779
Services billed
31,619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HizentraImmun Glob G(Igg)/Pro/Iga 0-5047$1,049,502
SolirisEculizumab12$638,729
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5013$275,029
Gamunex-CImmune Globul G/Gly/Iga Avg 4621$228,085
AustedoDeutetrabenazine29$176,422
GocovriAmantadine Hcl55$156,680
RytaryCarbidopa/Levodopa105$100,897
BotoxOnabotulinumtoxina71$92,354
NeuproRotigotine41$59,470
RexultiBrexpiprazole37$52,408
Aimovig AutoinjectorErenumab-Aooe54$51,825
Emgality PenGalcanezumab-Gnlm59$49,281
NuedextaDextromethorphan Hbr/Quinidine35$40,817
Nurtec OdtRimegepant Sulfate28$35,745
BriviactBrivaracetam15$34,825

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringHizentra$45$1,049,50247 claims
AstraZenecaSoliris$1,013$638,72912 claims
Teva Pharmaceuticals USA, Inc.Austedo$387$176,42229 claims
MDD US Operations, LLCGocovri$31$156,68055 claims
AbbVieBotox, Ubrelvy, Qulipta$997$123,968104 claims
Amneal Pharmaceuticals LLCRytary$243$100,897105 claims
UCB, Inc.Neupro, Briviact$276$94,29556 claims
Otsuka America Pharmaceutical, Inc.Rexulti$166$52,40837 claims
Avanir Pharmaceuticals, Inc.Nuedexta$236$40,81735 claims
PfizerNurtec Odt$14$35,74528 claims
SK Life Science, Inc.Xcopri$775$9,98011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,434 neurology providers in Florida.

Other neurology in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →